Methods for treating or preventing asthma by administering an IL-4R antagonist

A method for increasing forced expiratory volume in 1 second (FEV1) in liters to treat moderate to severe asthma in a subject in need thereof comprising administering to the subject a combination therapy comprising:

• i) one or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 600 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4 and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7 and 8, and
• iv) one or more secondary doses of 300 mg of the antibody,
• wherein the ICS and LABA are administered for the duration of administration of the antibody.

A method for improving one or more moderate to severe asthma-associated parameter(s) in a subject in need thereof comprising administering to the subject a combination therapy comprising:

• i.) One or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 600 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4 and 5, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs:
• 6, 7 and 8, and
• iv) one or more secondary doses of 300 mg of the antibody,
• wherein the ICS and LABA are administered for the duration of administration of the antibody.

A method for reducing an asthma patient's dependence on one or both of ICS and LABA for the treatment of one or more moderate to severe asthma exacerbations comprising:

• (a) selecting a patient who has moderate-to-severe asthma that is uncontrolled with a background asthma therapy comprising an ICS, a LABA, or a combination thereof;
• and
• (b) administering to the patient a combination therapy comprising:
• i) one or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 600 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4 and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7 and 8, and
• iv) one or more secondary doses of 300 mg of the antibody, wherein the ICS and LABA are administered for the duration of administration of the antibody.

A method for add-on maintenance treatment of moderate to severe asthma in a subject in need thereof comprising administering to the subject

• an initial dose of 400 mg of an antibody or that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, and
• one or more secondary doses of 200 mg of the antibody.

A method for increasing FEV1 in liters to treat moderate to severe asthma in a subject in need thereof comprising administering to the subject a combination therapy comprising:

• i) one or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 400 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, and
• iv) one or more secondary doses of 200 mg of the antibody,
• wherein the ICS and LABA are administered for the duration of administration of the antibody.

A method for improving one or more moderate to severe asthma-associated parameter(s) in a subject in need thereof comprising administering to the subject a combination therapy comprising:

• i) one or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 400 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, and
• iv) one or more secondary doses of 200 mg of the antibody,
• wherein the ICS and LABA are administered for the duration of administration of the antibody.

A method for reducing an asthma patient's dependence on one or both of ICS and LABA for the treatment of one or more exacerbations of moderate to severe asthma comprising:

• (a) selecting a patient who has moderate to severe asthma that is uncontrolled with a background asthma therapy comprising an ICS, a LABA, or a combination thereof;
• and
• (b) administering to the patient a combination therapy comprising:
• i) one or more maintenance doses of an ICS,
• ii) one or more maintenance doses of a LABA,
• iii) an initial dose of 400 mg of an antibody that specifically binds to IL-4R comprising three HCDR sequences comprising SEQ ID NOs:
• 3, 4, and 5, and three LCDR sequences comprising SEQ ID NOs:
• 6, 7, and 8, and
• iv) one or more secondary doses of 200 mg of the antibody,
• wherein the ICS and LABA are administered for the duration of administration of the antibody.